Lilly registers three new early trials: olomorasib in colorectal cancer, two obesity studies
Eli Lilly filed three trials this week, none yet recruiting, spanning a KRAS G12C colorectal cancer combination and two obesity-focused Phase 1 studies.
This week's registry activity shows Eli Lilly filing three new studies, all listed as not yet recruiting.
- Olomorasib (LY3537982), a KRAS G12C inhibitor, is being tested in a Phase 2 study combining it with cetuximab and mFOLFOX6 for KRAS G12C-mutant colorectal cancer that is locally advanced and unresectable or has metastasized.1 The study plans to enroll 50 participants.1
- LY4329090 is entering a Phase 1 single- and multiple-ascending dose study in participants who are obese or overweight but otherwise healthy,2 with an estimated enrollment of 184 participants.2
- Eloralintide (LY3841136) is the subject of a Phase 1 open-label study examining how the drug affects the pharmacokinetics of the combined oral contraceptive levonorgestrel-ethinyl estradiol in female participants with obesity or overweight.3 The study is expected to enroll 34 participants.3
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.